GenVec (GNVC) Says Novartis (NVS) Remains Committed to CGF166 Amid Internal Changes
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
GenVec (Nasdaq: GNVC) disclosed the following in a U.S. SEC filing on Thursday:
Item 7.01. Regulation FD Disclosure.
On August 31, 2016, press reports disclosed that Novartis (NYSE: NVS) is planning to eliminate its internal unit dedicated to cell and gene therapy and redeploy most of the affected employees. Novartis is developing CGF166, GenVec's lead product candidate for hearing loss, under a Research Collaboration and License Agreement between the two parties. Novartis has informed GenVec that it remains engaged on the CGF166 program and that Novartis's internal changes are not expected or intended to reduce its support for the program.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bill Barrett Corporation (BBG) Entered Confidentiality Agreement with Bonanza Creek Energy (BCEI) Pertaining to BCEI's Chapter 11 Proceeding
- NCR Corp. (NCR) Reports Agreement to Conclude Fox River Environmental Matter
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot Corp. News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!